Search
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Cetyl alcohol
go.drugbank.com/drugs/DB09494ApprovedCetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [A32209]. … Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol [A32209]. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions.
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. … [L4562] Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic
Categories: Antivirals used in combination for the treatment of HIV infectionsVestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalIn clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with … Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients.
Alternaria alternata
go.drugbank.com/drugs/DB10424ApprovedAlternaria alternata extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureRegdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Ublituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigationalCD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[L4799] Other biosimilars include adalimumab-fkjp - which was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935], adalimumab-aacf - which was approved in October … [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.
International brands: Humira PenProducts: AMGEVITA 40MG ILO I E PEN, AMGEVITA 40 MG ILO I E PENTeduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalFDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalIn July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.